Homoharringtonine as a Rapid SARS-CoV-2 Inhibitor: Study Insights

Study Background and Research Question

The ongoing threat of coronavirus epidemics underscores the urgent need for broad-spectrum antivirals that act both rapidly and safely. The reference study, published in National Science Review (Wen et al., 2025), addresses this need by investigating homoharringtonine (HHT)—a plant-derived cytotoxic alkaloid long established in leukemia research—as a potential first-line therapeutic against SARS-CoV-2 and related coronaviruses. The study's central question is whether HHT's well-characterized mechanism as a eukaryotic 80S ribosome inhibitor can be leveraged to achieve swift viral clearance in the upper respiratory tract, thereby interrupting transmission and reducing disease burden early in infection.

Key Innovation from the Reference Study

Wen et al. introduce a protocol-driven scheme for using homoharringtonine to eliminate SARS-CoV-2 from the upper respiratory tract within 2–4 days post-infection. This approach capitalizes on HHT's ability to inhibit protein chain elongation, thereby suppressing the synthesis of viral proteins required for replication. Notably, the study demonstrates that a low, localized dose delivered via nasal spray or nebulization is sufficient to achieve rapid viral clearance while minimizing systemic exposure and adverse effects. The innovation lies in both the mechanistic repurposing of a cytotoxic alkaloid for antiviral use and the evidence-based delivery strategy aimed at early-stage infection control.

Methods and Experimental Design Insights

The research employed a multi-layered strategy, including in vitro, in vivo, and clinical assessments:

• In vitro assays: HHT was tested against four human coronaviruses, including SARS-CoV-2, at nanomolar concentrations. Viral replication and protein synthesis were measured following compound exposure.
• Animal model studies: Mice infected with SARS-CoV-2 received daily nasal drips of 40 μg HHT. Viral loads in the upper respiratory tract were measured at defined intervals.
• Clinical evaluation: Two small trials were conducted. In December 2022, 26 cancer patients received 1 mg/day HHT via nebulization. In May 2023, 11 non-cancer patients received repeated nasal sprays (total daily dose 0.2 mg).

The investigators also tracked adverse effects and compared viral clearance rates with historical and contemporaneous COVID-19 patient cohorts in China.

Core Findings and Why They Matter

Key results from the study include:

• Potent antiviral action: HHT inhibited replication of all tested coronaviruses in cell culture at nanomolar concentrations, confirming its broad-spectrum potential against the viral family.
• In vivo efficacy: In animal models, daily nasal administration of HHT cleared SARS-CoV-2 from all treated mice within three days (reference study).
• Clinical clearance: In cancer patients, nebulized HHT led to a three-quarters reduction in upper respiratory tract viral load within six hours. In non-cancer patients, 10 out of 11 cleared the virus in 2–4 days. For comparison, most patients in large-cohort studies required 7–9 days to achieve viral negativity during the same epidemic period.
• Safety profile: No adverse effects were observed in either trial, despite HHT’s cytotoxic nature.

These findings are significant because they support the concept that a protein synthesis inhibitor can serve as a rapid-acting antiviral. Early viral clearance from the upper respiratory tract is crucial for reducing both disease progression and transmission risk, making HHT a candidate for first-line intervention during future outbreaks.

Comparison with Existing Internal Articles

The translational significance of these findings is contextualized by several internal resources:

• "Homoharringtonine as a Rapid SARS-CoV-2 Inhibitor: Molecular Insights" highlights HHT’s established role in leukemia research and its mechanistic bridge to antiviral use. This article underscores the compound’s dual-domain relevance, supporting the cross-application strategy validated by the reference study.
• "Homoharringtonine: Mechanistic Innovation for Translational Research" provides detailed discussion of ribosomal inhibition as a unifying principle in cancer biology and infectious disease, aligning closely with Wen et al.’s mechanistic rationale.
• "Homoharringtonine Clears SARS-CoV-2: Mechanism and Evidence" reinforces the evidence for rapid upper respiratory tract viral clearance and the potential for deployment in future pandemics.

The reference study advances these perspectives by adding robust clinical and preclinical data, particularly on dosage, administration route, and comparative timelines for viral clearance.

Protocol Parameters

• In vitro antiviral testing: Homoharringtonine at nanomolar concentrations (exact values as per Wen et al., 2025), added to cell cultures prior to viral challenge.
• Animal model administration: Daily nasal dripping of 40 μg HHT in mice, initiated immediately post-infection and continued for up to three days.
• Clinical protocol (cancer patients): Nebulization at 1 mg/day, assessing upper respiratory tract viral load 6 hours post-administration.
• Clinical protocol (non-cancer patients): Repeated nasal spray totaling 0.2 mg HHT per day, continued until viral clearance (typically 2–4 days).
• Product handling recommendations: Homoharringtonine is insoluble in water, but highly soluble in ethanol and DMSO. For optimal stability, store at –20°C (product information).

These parameters provide a practical starting point for researchers designing similar workflows, with adaptations as needed for institutional biosafety and regulatory requirements.

Why this cross-domain matters, maturity, and limitations

Homoharringtonine’s transition from a cytotoxic agent in leukemia to a targeted antiviral against SARS-CoV-2 exemplifies the value of mechanistic repurposing. Its inhibitory effect on the eukaryotic 80S ribosome is relevant in both cancer biology (inducing cell cycle G1 phase arrest) and antiviral defense (blocking viral protein synthesis). The maturity of this approach is supported by peer-reviewed clinical and preclinical data, yet several limitations remain:

• Limited cohort size: The clinical studies included small patient populations, with no placebo control group.
• Short-term follow-up: Adverse effects were monitored only in the acute phase; longer-term safety remains to be established, especially in non-cancer populations.
• Transferability: While the protocol is promising for early infection and upper respiratory tract targeting, its efficacy in severe, systemic COVID-19 or against future divergent coronaviruses requires further validation.

The cross-domain mechanism also raises important workflow considerations for researchers, as the compound’s cytotoxicity demands careful titration and handling, especially in translational or human studies.

Research Support Resources

Researchers interested in replicating or extending these protocols can utilize Homoharringtonine (SKU N1504) from APExBIO, which is formulated for high solubility in DMSO and ethanol and is suitable for both cancer biology and SARS-CoV-2 antiviral research. Its established use in cell cycle and viral replication workflows makes it a practical choice for cross-domain translational studies. As always, ensure that all protocols comply with institutional biosafety regulations and ethical guidelines.